Plasma β-endorphin levels in obese and non-obese patients with polycystic ovary disease

Gynecological Endocrinology

Volumn 15, Issue 1, 2001, Pages 14-22

  Martinez Guisasola J ^a   Guerrero, M ^b   Alonso, F ^a   Diaz F ^c   Cordero, J ^a   Ferrer, J ^c  

^a HOSPITAL UNIVERSITARIO DE BURGOS   (Spain)

^b HOSPITAL SANTOS REYES   (Spain)

^c UNIVERSITY OF OVIEDO   (Spain)

Author keywords

Insulin; Obesity; Opioid Peptides; Polycystic Ovary Disease; Endorphin

Indexed keywords

ANDROGEN; BETA ENDORPHIN; ESTRADIOL; ESTRONE; GONADOTROPIN; INSULIN; LUTEINIZING HORMONE; PROGESTERONE; PROLACTIN; SEX HORMONE BINDING GLOBULIN; STERYL SULFATASE;

ADOLESCENT; ADULT; ANDROGEN BLOOD LEVEL; ARTICLE; BASAL METABOLIC RATE; BLOOD SAMPLING; BODY WEIGHT; ESTRADIOL BLOOD LEVEL; ESTRONE BLOOD LEVEL; FEMALE; GONADOTROPIN BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULINEMIA; LUTEINIZING HORMONE BLOOD LEVEL; MAJOR CLINICAL STUDY; OBESITY; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; PROGESTERONE BLOOD LEVEL; PROLACTIN BLOOD LEVEL; PROTEIN BLOOD LEVEL; REGRESSION ANALYSIS; VENOUS BLOOD;

EID: 0035077721     PISSN: 09513590     EISSN: None     Source Type: Journal    
DOI: 10.1080/gye.15.1.14.22     Document Type: Article

References (46)

1. The hypothalamic control of the menstrual cycle and the role of endogenous opioid peptides
2. Neuroendocrinology of opioid peptides and their role in the control of gonadotropin and prolactin secretion
3. Opioid control of luteinizing hormone secretion in humans
4. The role of neurotransmitters and opioids in polycystic ovarian syndrome
5. Impairment of opioid control of luteinizing hormone secretion in menstrual disorders
6. Central opioid activity in polycystic ovary syndrome with and without dopaminergic modulation
7. β-endorphin and β-lipotropin plasma levels in hirsute women: Correlation with body weight
8. Neuroendocrine control in polycystic ovary like syndrome
9. Evidence for decreased endogenous dopamine and opioid inhibitory influences on LH secretion in polycystic ovary syndrome
10. Opioidergic regulation of LH pulsatility in women with polycystic ovary syndrome
11. Alterations in opioid parameters in the hypothalamus of rats with estradiol induced polycystic ovary syndrome
12. Increased circulating levels of immunoreactive β-endorphin in polycystic ovary syndrome is not caused by increased pituitary secretion
13. Elevated plasma levels of β-endorphin in a group of women with polycystic ovarian syndrome
14. Elevated levels of plasma β-endorphin and alpha 3 melanocyte stimulating hormone in polycystic ovary syndrome
15. Plasma β-endorphin in obese and non-obese patients with polycystic ovarian disease
16. The influence of the body weight to β-endorphin plasma levels in a group of women with polycystic ovarian disease
17. Circulating levels of β-immunoreactive β-endorphin in polycystic ovary syndrome
18. β-endorphin is associated with overeating in genetically obese mice (ob/ob) and rats (fa/fa)
19. Opioid peptides and melanocyte stimulating hormone in genetically obese (ob/ob) mice during development
20. Studies on the role of opiate peptides in two forms of genetic obesity: ob/ob mouse and fa/fa rat
21. The polycystic ovary syndrome
22. Effect of insulin on steroidogenesis in cultured porcine ovarian cells
23. Differences in clinical and endocrine features between obese and non-obese subjects with polycystic ovary syndrome: An analysis of 263 consecutive cases
24. Clinical features and circulating gonadotropin, insulin and androgen interactions in women with polycystic ovarian disease
25. Hypersecretion of androstenedione by isolated thecal cells from polycystic ovaries
26. The relationship of insulin to sex hormone binding globulin levels in obese women with polycystic ovary syndrome: Role of adiposity
27. A direct effect of hyperinsulinemia on serum sex hormone binding globulin levels in obese women with the polycystic ovary syndrome
28. β-endorphin in the human pancreas
29. Long term naltrexone treatment reduces the exagerated insulin secretion in patients with polycystic ovarian disease
30. Effect of opioid blockade on insulin metabolism in polycystic ovarian disease
31. Report of the expert committee on the diagnosis and classification of diabetes mellitus
32. Insulin, C-peptide, androgens and β-endorphin response to oral glucose in patients with polycystic ovary syndrome
33. Naltrexone reduces weight gain, alters β-endorphin, and reduces insulin output from pancreatic islets of genetically obese mice
34. Pain perception and serum β-endorphin in trauma patients
35. Dexamethasone fails to suppress hyperendorphinaemia of obese children
36. Gonadal-steroid induced modification of opiate binding sites in anterior hypothalamus of female rat
37. The role of aberrant hypothalamic opiatergic function in generating polycystic ovaries in the rat
38. Brain peptides
39. Ovarian follicular fluid β-endorphin levels in normal and polycystic ovaries
40. Insulin secretion in polycystic ovarian disease: Effect of ovarian suppression by GnRH agonist
41. Effect of naloxone on plasma insulin, insulin-like growth factor I, and its binding protein 1 in patients with polycystic ovarian disease
42. β-endorphin infusion restores acute insulin response to glucose in type II diabetes mellitus
43. Reduction of hyperinsulinemia and insulin resistance by opiate receptor blockade
44. Effect of opiate receptor blockade on the insulin response to oral glucose load in polycystic ovarian disease
45. Clinical and hormonal characteristics of obese amenorrheic hyperandrogenic women before and after weight loss
46. Effect of insulin-like growth factor type I (IGF I) and insulin on the secretion of sex hormone binding globulin and IGF I binding protein by human hepatome cells